Compositions and methods for inhibiting viral activity
AssigneeThe Regents of the University of California
InventorJay A. Levy
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide.
Claims26
A method of inhibiting the activity of a virus in an individual, the method comprising:
- administering to the individual an effective amount of an anti-viral composition comprising at least one anti-viral agent selected from:
- an sCD137 polypeptide, a nucleic acid comprising a nucleotide sequence that encodes an sCD137 polypeptide, a FAM3C polypeptide, and a nucleic acid comprising a nucleotide sequence that encodes a FAM3C polypeptide,
- wherein the individual is infected with the virus, has an increased risk of being infected with the virus, or is suspected of being infected with the virus.
A method of inhibiting viral activity in a target cell that is infected with a virus, has an increased risk of acquiring a virus, or is suspected of having a virus;
- the method comprising at least one of:
- (i) contacting the target cell with an effective amount of an anti-viral composition comprising at least one anti-viral agent selected from:
- an sCD137 polypeptide, and a FAM3C polypeptide;
- and
- (ii) introducing into the cell an anti-viral composition comprising at least one anti-viral agent selected from:
- a nucleic acid comprising a nucleotide sequence that encodes an sCD137 polypeptide, and a nucleic acid comprising a nucleotide sequence that encodes a FAM3C polypeptide.
Dependencies are inferred from the claim text.